Skip to main navigation Skip to search Skip to main content

A randomized phase 3 study of MRTX849 versus Docetaxel in patients with previously treated non small cell lung cancer with KRAS G12C mutation

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date05/20/21 → 05/9/24

Funding

  • Mirati Therapeutics Incorporated: $104,424.68